Edwards Lifesciences is projected to deliver steady profit and revenue growth through 2026. Click here to read more on EW ...

Edwards Lifesciences (EW) stock and Medtronic (MDT) stock gain as Boston Scientific (BSX) halts sales of ACURATE heart valves ...

This was the stock's fourth consecutive day of gains.

This was the stock's second consecutive day of gains.

Detailed price information for Edwards Lifesciences Corp (EW-N) from The Globe and Mail including charting and trades.

Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Investors responded positively to the news, boosting Edwards Lifesciences’ stock during the trading session. The company, which is a leading player in the heart valve market, may now face less ...

A Relative Strength Rating upgrade for Edwards Lifesciences shows improving technical performance. Will it continue?

Edwards Lifesciences (NYSE:EW) saw its shares rise by 3% following news that competitor Boston Scientific (NYSE:BSX) is ...

St. Luke’s Heart Team pioneers first EVOQUE tricuspid valve replacement in the region, offering new hope for patients with ...

Abbott said the Tendyne system addresses a significant unmet need in cardiac care, providing an option for patients ineligible for open heart surgery and whose valves cannot be successfully repaired ...

Boston Scientific has discontinued global sales of its Acurate neo2 and Acurate Prime transcatheter aortic valve replacement ...